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2012.05.0Abstract Background: Understanding the role of environmental and molecular inﬂuences on the
nature and rate of K-ras mutations in colorectal neoplasms is crucial. COX-2 polymorphisms
765G > C may play a role in carcinogenic processes in combination with speciﬁc life-style condi-
tions or dependent on the racial composition of a particular population.
If mutational events play an important role in colorectal carcinogenesis sequence, one can hypoth-
esize that modiﬁcation of these events by life-style or other factors would be a useful prevention
strategy.
Aim of work: To explore the association between K-ras mutation and potential variables known or
suspected to be related to the risk of colorectal cancer (CRC) as well as determining the possible
modulating effect of the COX-2 polymorphism, 765G> C.
Subjects and methods: The study was conducted on 80 patients with colorectal cancer from Trop-
ical Medicine and Gastrointestinal Tract endoscopy Departments and those attending clinic of the
National Cancer Institute, Cairo University during the period extending from April 2009 to March
2010.
Full history taking with emphasis on the risk factors of interest, namely age, sex, family history,
smoking and dietary history. Serum CEA and CA19-9, RBCs folic acid and occult blood in stool47800104.
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116 M.M. Kamal et al.were done to all samples. K-ras protooncogene mutation at codon 12 (exon 1) and cyclooxygenase 2
(COX-2) 765G > C polymorphism were determined by PCR-RFLP.
Results: The K-ras mutation was positive in 23 (28.7%) patients. COX-2 polymorphism revealed
GG in 62.5%, GC in 26.2 % and CC genotype was found in 11.3 % of cases.
The mean red blood cell folic acid level was lower in the K-ras positive group (100.96 ± 51.3 ng/ml)
than the negative group (216.6 ± 166.4 ng/ml), (P< 0.01). Higher folate levels were found in males
than females (median = 173 ng/ml and 85 ng/ml; respectively, P= 0.002) with adjusted odds ratio
(OR) of 0.984.
Only, the RBCs folate (P= 0.0018) followed by gender (P= 0.036) contributed signiﬁcantly in the
discrimination between patients prone to develop K-ras mutation and those who are not.
Conclusion: RBC folic acid was signiﬁcantly deﬁcient in CRC (colorectal cancer) patients with K-
ras mutations in comparison with CRC patients free of the mutations, suggesting that folic acid
may be a risk factor for K-ras mutation development.
ª 2012 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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Colorectal cancer (CRC) is a major health problem in industri-
alized countries [1]. It is the second most commonly diagnosed
cancer in the USA [2]. It has been postulated that approxi-
mately 80% of the observed differences in incidence rates be-
tween countries can be attributed to dietary factors [3].
In Egypt, colorectal carcinoma is one of the most common
malignant neoplasms and the third leading cause of death. It
represents about 6% of cancers in Egypt (after bladder, breast
carcinoma and lymphoma) with high male predominance 3:1
and more than 1/3 under age 45 years. It is rectal in 51% of
the cases. Associated bilharzial colitis is present in 12% of
the cases and associated polyps are found in 5%. About 5%
of the cases occur as a hereditary non-polyposis colorectal can-
cer (HNPCC) [4].
In 2002, a large body of evidence indicated that some die-
tary and genetic factors were likely to have a major inﬂuence
on the risk of colon cancer. Among the dietary factors is the
high consumption of red meat, tea, coffee and low consump-
tion of green leafy vegetables [5].
As regards genetic factors, progresses made in the ﬁeld of
molecular biology have shed light on two important genes
implicated in colorectal carcinoma namely cyclooxygenases
(COX-2) and Kirsten-Ras (K-ras) [6].
Kirsten-Ras gene which is thought to be critical in the
development of colorectal cancer is present on chromosome
12, and it encodes for p21 Ras [7]. Activating mutations of
K-ras occurring early in colorectal tumor genesis are thought
to abolish GTPase activity and render the protein resistant
to inactivation by regulatory GTPase activating proteins, lock-
ing the ras protein in the active GTP bound state leading to in-
creased and unregulated cellular proliferation and malignant
transformation [8].
Despite the high frequency of K-ras mutations in colorectal
neoplasms, data on their etiology are sparse [9]. In addition,
different authors discovered that colon cancers in patients
from different geographic areas are different because different
genes are being mutated or abnormally regulated [10,11].
Undoubtedly, understanding the inﬂuential that may affect
the rate of these mutations in colorectal neoplasm is crucial.
One can hypothesize that modiﬁcation of these events by life-
style or other factors would be a useful prevention strategy.Many risk factors are accused in the causation of K-ras
mutations. Heredity may play a role, however, most cases
show history of exposure to environmental risk factors, includ-
ing dietary factors especially red meat consumption, tea and
coffee consumption, smoking, alcoholism and chronic folate
deﬁciency [12].
COX-2 plays major roles in the inﬂammatory response [13].
It is well established that patients with inﬂammatory bowel
disease are at increased risk of developing colorectal cancer
(CRC) [14]. A common promoter variant, 765G > C
(rs20417), a G to C transversion resulting in signiﬁcantly lower
promoter activity, and reduced levels of C-reactive protein
(CRP) which is a systemic marker of inﬂammation [15]. It
has been reported that this polymorphism modiﬁes the risk
of colorectal cancer [16]. Cyclooxygenase-2 expression in colo-
rectal adenoma cells is strongly correlated with K-ras gene
mutation, suggesting that COX-2 and mutated K-ras are con-
nectively associated with the progression of colorectal ade-
noma [17].
The aim of this study was to explore the association be-
tween K-ras mutation and potential variables known or sus-
pected to be related to the risk of CRC, as dietary habits,
smoking status, and folic acid level adjusted for patient char-
acteristics as well as COX-2 promoter polymorphism
(765G > C) as a common genetic abnormality in these
patients.
Subjects and methods
Study population
This retrospective cohort study was conducted in Kasr El Aini
Hospital on patients attending Tropical Medicine and Gastro-
intestinal Tract endoscopy Departments and those attending
the clinic of the National Cancer Institute, Cairo University
during the period extending from April 2009 to March 2010.
The study included 80 patients recently proven to have
colorectal cancer by histological examination (56 males and
24 females).
A logistic regression of a binary response variable (Y) on a
binary independent variable (X) with a sample size of 80 obser-
vations (of which 30% are in the group X= 0 and 70% are in
the group X= 1) achieves 80% power at a 0.05000 signiﬁ-
Figure 1 Genotyping of K-ras mutation for eight samples,
sample no 4 harbors the mutant K-ras allele (143 bp, 114-bp
fragments) in a heterozygous manner while others harbor the wild
allele (114-bp fragment). The ﬁrst lane with ladder marker (50 bp).
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baseline value of 0.3–0.561. An adjustment was made since a
multiple regression of the independent variable of interest on
the other independent variables in the logistic regression ob-
tained an R-Squared of 0.100 [18].
Written consent was taken from all subjects and approval
of the local ethics committee was obtained before this study.
All patients were subjected to full history taking with emphasis
on the risk factors of interest, namely age, sex, family history
of previous CRC, special habits of medical importance (smok-
ing) and dietary history (meat and vegetables consumption
using related parts derived from the National Health and
Nutrition Examination Survey (NHANES) food frequency
questionnaire) [19]. The questionnaire contained several ques-
tions regarding dietary intake 1 year ago. For example: ‘‘how
often a fruit/vegetable serving was eaten’’, ‘‘how often a red
meat serving was eaten’’. Validity of questionnaire was tested
by presenting to other experts in this ﬁeld of study and was
modiﬁed when necessary.
The cases were subjected to full clinical examination,
abdominopelvic ultrasound, CT, chest X-ray, lower gastroin-
testinal endoscopy (colonoscopy), laboratory investigations.
Laboratory assessment
Stool samples were taken for testing occult blood. Occult
blood was tested by immunochemical assay using monoclonal
antibody against human globin, supplied by Acon (ACON
Laboratories, Inc. 4108 Sorrento Valley Boulevard San Diego,
CA 92121, USA).
Fasting blood samples were withdrawn from each patient
(8 ml), divided into 3 aliquots:
Routine chemistry and tumor markers
Blood (4ml) was put in plain tube and serum was used for rou-
tine chemical investigations (liver enzymes, urea and creati-
nine) and tumour markers. All routine chemistry analyzers
were analyzed on the automated Roche 917 analyzer, by kits
supplied by Roche diagnostics (Roche Diagnostics GmbH,
D-68298 Mannheim).
Serum CEA was analyzed by solid phase, two-site chemilu-
minescent enzyme immunometric assay on the Immulite auto-
analyzer. The instrument and the kits were supplied by
Seimens healthcare diagnostics (1717 Deerﬁeld Road Deer-
ﬁeld, IL 60015-0778, USA).
CA19-9 was assayed in serum samples by electrochemilumi-
nescent assay on Elecsys 1010 system. The instrument and the
kits were supplied by Roche Diagnostics. The procedure was
done according to the manufacturer’s instructions.
Folic acid and hematocrite
Two ml blood was put on EDTA tube for RBC folic acid and
hematocrite assay. Folic acid was assayed in blood samples by
Competitive Chemiluminescent enzyme immunoassay on the
Immulite autoanalyzer. Whole blood folate was assayed ﬁrst
in an hemolysate (1 part EDTA blood + 20 parts freshly pre-
pared 1% ascorbic acid). This value is then converted into
RBC folate according to the following equation: Red Cell Fo-
lic Acid = whole blood folic acid (corrected for the 21-fold
dilution) · (100/haematocrite). The instrument and the kits
were supplied by DPC-Seimens [20].DNA extraction and genotyping
Genomic DNA was extracted from two ml of venous blood on
EDTA using proteinase K digestion followed by a salting out
procedure based on the method described by [21].
Mutations at codons 12 of exon one of the K-ras gene were
detected by an enriched semi-nested polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP)
[22]. The ﬁrst round ampliﬁcation was performed using the pri-
mer DD5P: 50 TCATGAAAATGGTCAGAGAA 30, and to
create the restriction site for BstNI [CCTGG] that is lost when
a K-ras codon 12 mutation exists, we used the mutant primer
K-ras 50: 50ACTGAATATAAACTTGTGGTAGTTGGA
CCT 30 for 10 cycles (Denaturation at 92 C for 15 s, annealing
at 44 C for 15 s and extension at 72 C for 15 s). Ampliﬁcation
was done in Hybaid thermal cycler supplied by Promega (Pro-
mega Corporation 2800 Woods Hollow Road Madison, WI
53711, USA).This was followed by Restriction Enzyme Cleav-
age using the BstN1 restriction enzyme.
The digested product was reampliﬁed using the second
round ampliﬁcation with the previous primer K-ras 50 together
with K-ras 30 primer (50TCAAAGAATGGTCCTGGACC 30)
for 35 cycles (92 C for 15 s , annealing at 54 C for 15 s and
extension at 72 C for 15 s). The latter primer artiﬁcially intro-
duces an internal control to assure the completion of enzy-
matic digestion. This was followed by digestion of 5 ll of the
ampliﬁed product using the BstN1 enzyme.
After agarose gel electrophoresis (4%) using electrophoresis
apparatus and ethidium bromide stain (0.5 mg/mL), the point
mutation was detected by ultra violet light transillumination.
The 143 base pair (bp) band depicts the mutant allele, and
the 114-bp band depicts the normal allele, Fig. 1.
The COX-2 765G > C genotypes were determined by the
PCR-RFLP assay [16]. The target sequence was ampliﬁed
using the following primers: 50-GGCTGTATATCTGCTCTA-
TATGC-30 (forward) and 50-CCGCTTCCTTTGTCCAT-
CAG-30 (reverse). Ampliﬁcation was performed for 1 min at
94C followed by 35 cycles of 30 s at 94 C, 30 s at 59 C,
and 30 s at 72 C, with a ﬁnal step at 72 C for 1 min. The
PCR products were then digested with Aci1 (New England
BioLabs) and separated on agarose gel electrophoresis (4%).
After electrophoresis, homozygous C allele was represented
by a DNA band sized at 306 bp, whereas homozygous G allele
Figure 2 Genotyping of COX-2-765G>C polymorphism by
PCR-RFLP Homozygous C in lane1–3, homozygous G in lane 4,
6, while, lane 5 shows heterozygous GC. Marker (Ladder 50 bp)
was used.
Table 1 Basic characteristics of the studied patients with
colorectal cancer.
Characteristics Value
Age (years)a 57.03 ± 10.4
Sex
Male 56 (70)
Female 24 (30)
Family history
of CRC
Positive 12 (15)
Negative 68 (85)
Dietary pattern
Red meat
1–3/month 4 (5)
1–2/w 9 (11.25)
3–4/w 28 (35)
5–7/w 39 (48.75)
Green leafy
vegetables
1–3/month 28 (35)
1–2/w 19 (23.75)
3–4/w 11 (13.75)
5–7/w 22 (27.5)
Tea and coﬀee
intake/day
None 9 (11.25)
1–3/day 46 (57.5)
4–6/day 20 (25)
6 or more/day 5 (6.25)
Smoking
Yes 39 (48.75)
No 41 (51.25)
a All data are frequency (%) except for the age (mean ± SD).
118 M.M. Kamal et al.was represented by a DNA band sized at 118 bp and 188 bp,
and heterozygotes sized at 306 bp, 118 bp and 188 bp, Fig. 2.
Data analysis
Quantitative data were summarized as mean and standard
deviation (if normally distributed) and as median and inter-
quartile range (25–75th percentiles) for non-normal data. All
variables were ﬁrst examined by means of univariate analysis
to assess the importance of each of them on the K-ras muta-
tion. They were compared by student t-test or by Mann–Whit-
ney test as appropriate. Qualitative data were summarized as
percent and compared by chi-square test.
Forward stepwise logistic regression analysis was run to se-
lect the minimum combination of variables that maximally dis-
criminates between patients prone to develop K-ras mutation
and those who are not. K-ras mutation was used as the (bin-
ary) dependent variable; while the initial selection of indepen-
dent (explanatory) variables in this model was based on
clinical experience and medical literature.
A speciﬁc model was produced; in addition, the proportion
of explained variance R2 was calculated. For all variables, odds
ratio estimates with corresponding 95% Wald CIs are
presented.
Logit (P) which is the natural log of the odds of occurrence
of K-ras mutation is converted into probability (P) of K-ras
mutation either by looking its value in logit table [23] or by
using the following equation:
P ¼ 1
1þ elogitðPÞ
P values >0.5 predict K-ras mutation, while values <0.5 sug-
gest no mutation. The predicted probability of mutation was
calculated for the 80 studied CRC patients and was compared
against their actual mutation found.
Statistical analysis was run on SPSS for Windows, re-
lease.11.0. P values <0.05 were considered statistically
signiﬁcant.
Results
This study was conducted on 80 colorectal cancer patients pro-
ven by histopathological examination. Their mean age was
57.03 years with minimum of 20 years and maximum of75 years of age. The characteristics of the patients under study
are shown in Table 1. The group included 56 (70%) males and
24 (30%) females.
Dietary history revealed the following data:
Most of the patients (83.7%) reported red meat consump-
tion at a frequency of 3–7 times/week. Approximately half of
the patients reported intake of green leafy vegetables at the
same frequency, while intake at a frequency of 1–3 per month
was reported by one third of them. Daily consumption of tea
and coffee was recorded in 98.75% of the patients. Smoking
was present in 49% of the cases, Table 1.
Results of all laboratory investigations are listed in Table 2.
The K-ras mutation was present in 28.7% of the patients.
Cyclooxygenase 2 (COX-2) 765G> C polymorphism re-
vealed GG, n= 50 (62.5%), GC, n= 21 (26.2 %) and CC
genotype in 9 cases (11.3 %).
By comparison of the resulting data of the K-ras mutation
positive group and the mutation negative group as shown in
Table 3, there was no statistical signiﬁcant difference regarding
age, sex distribution and family history in the two groups.
Also, the dietary data showed that mean meat consumption
per week and the green leafy vegetables consumption among
the mutation positive group did not vary signiﬁcantly from
the negative group. The situation was the same regarding the
Table 2 Laboratory ﬁndings of the studied patients with
CRC.
Laboratory ﬁndings Values
AST (U/L) 30 (23–37)
ALT (U/L) 29 (21–35.7)
Urea (mg/dl) 33 (23–37)
Creatinine (mg/dl) 0.67 (0.52–0.83)
Fecal occult blood (positive)a 79 (98.8)
RBCs folic acid (ng/ml) 92.5 (84.2–254.8)
CEA (ng/ml) 34.4(42.1–48)
CA19-9 (U/ml) 250 (94.2–416.2)
K-ras genotypea
Mutation 23 (28.75%)
No mutation 57 (71.25%)
COX-2 genotypea
GC+ CC 30 (37.5 %)
GG 50 (62.5 %)
All data are presented as median (25–75th percentiles), unless
otherwise indicated.
a Frequency (%).
Table 3 Distribution of different variables according to K-ras mut
Variables Mutation +ve (23)
Age, yearsa 58.13 ± 10.9
Sexb
Male 18 (23.1)
Female 5 (20.8)
Family historyb
Positive 2 (16.7)
Negative 21 (30.9)
Dietary patternb
Meat
<3 times/week 9 (23.1)
P3 times/week 14 (34.1)
Green leafy vegetables
<3 times/week 15 (34.1)
P3 times/week 8 (22.3)
Tea and coﬀee intake/day
<3 times/day 10 (25.6)
P3 times/day 13 (29.5)
Smokingb
Yes 11 (28.2)
No 12 (29.3)
Lab ﬁndings
AST (U/L) 31 (20–38)
ALT (U/L) 28 (18–37)
Urea (mg/dl) 31 (23–37)
Creatinine (mg/dl) 0.63 (0.5–0.82)
RBCs folic acid (ng/ml) 85 (76.4–92.7)
Tumor marker levels
CEA (ng/ml) 29.6 (24.1–51)
CA19-9 (U/ml) 257 (108–493.3)
COX-2 geneb
GC+ CC 8 (26.7)
GG 15 (30)
All data are presented as median (25–75th percentiles), unless otherwise
a Mean ± SD.
b Frequency (%).
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median laboratory ﬁndings also, did not vary signiﬁcantly be-
tween the two groups. However, the red blood cell folic acid
level was much lower in the positive group than the negative
group and this difference was highly signiﬁcant statistically,
P= 0.002.
Folic acid concentration was higher in males (med-
ian = 173.5 ng/ml, 95% CI: 86.9–290.5) than in females (med-
ian 85 ng/ml, 95% CI: 79.3–116.4), P= 0.002. Other variables
did not differ between males and females.
Forward stepwise logistic regression was run to select the
minimum combination of variables that maximally discrimi-
nates between patients prone to develop K-ras mutation and
those who are not, so as to construct a prediction model to
help the prediction of those having a higher probability to de-
velop K-ras mutation. K-ras mutation was used as the (binary)
dependent variable ; while RBCs folate level, gender, age,
smoking, family history of CRC, CEA, CA19-9, consumption
of meat and green leafy vegetables, COX-2 genotype were en-
tered as independent (predictor) variables, Table 4. Only, the
RBCs folate (P= 0.0018) followed by gender (P= 0.036)ation in patients with CRC.
Mutation ve (57) P value
50.18 ± 8.9 0.25
38 (76.9) 0.31
19 (79.2)
10 (83.3) 0.32
47 (69.1)
30 (76.9) 0.25
27 (65.9)
29 (65.9) 0.08
28 (77.7)
26 (74.4) 0.09
31 (70.5)
28 (71.8) 0.92
29 (70.7)
30 (223–37) 0.59
29 (21–35) 0.90
33 (22–39) 0.45
0.68 (0.52–0.82 0.27
187 (87.9–288.2) 0.002
36.4 (24.4–48.2) 0.39
250 (90.3–371.5) 0.37
22 (73.3) 0.75
35 (70)
indicated.
Table 4 Comparison of the predicted probability of mutation
for the studied patients with CRC and their actual K-ras
mutation.
Observed Predicted
K-ras Percentage correct
ve +ve
K-ras ve 48 9 84.2
+ve 11 12 52.17
Overall percentage 75
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prone to develop K-ras mutation and those who are not. This
model accounted for 35.4% of the total variance in the depen-
dent variable (mutation occurrence).
Logistic regression analysis yielded the following equation:
LogitðPÞ ¼ 0:017Folateþ 1:61Sexþ 1:28
where folate is RBCs folate in ng/ml, sex is coded as 1 for
males and 0 for females, 0.017 and 1.61 are their respective
regression coefﬁcients and 1.28 is a constant. The adjusted
odds ratio (OR) for RBC folic acid was 0.983 (95%CI
0.974–0.994) and the OR for sex was 4.36 (95% CI 1.277–
15.717).
Table 4 showed the predicted probability of mutation when
compared against their actual mutation status and it demon-
strates that the overall predictive accuracy was 75% (60 out
of 80 were correctly diagnosed). Prediction of no mutation
was better (48 out of 59; speciﬁcity = 84.2%) than prediction
of mutation (12 out of 21; sensitivity = 52.17%).
Discussion
In this study K-ras mutation was found in 29% of the 80 pa-
tients suffering from colorectal cancer. We found that RBC fo-
lic acid was signiﬁcantly deﬁcient in CRC patients with K-ras
mutations in comparison with CRC patients free of the muta-
tions, suggesting that folic acid may be a risk factor for K-ras
mutation development.
Our study aimed at investigating the association between
potential variables known or suspected to be related to the risk
of colorectal cancer and the occurrence of K-ras mutation thus
explaining how such variables play a role in CRC tumorigen-
esis; whether risky or protective role. Fulﬁlling this aim would
contribute better to our understanding of CRC pathogenesis,
elaborate more on the use of K-ras mutation in CRC diagnos-
tic work-up and underscore protective factors that should be
recommended and risk factors that might be avoided.
Almost 90% of CRC is diagnosed in people aged 50 years
or older [24] and it predominates in males more than in females
[25]. This ﬁnding is consistent with our results where the mean
age of patients with mutation positive was 58 years with males
predominant in 78.3%.
A mutated K-ras gene contributes to the transition of an
intermediate adenoma to a late adenoma or carcinoma
[12,26,27]. Our ﬁgure (29%) exceeds the ﬁgure reported by Na-
guib et al. study (22%) who recommended further work to
identify the molecular background of CRC in UK [28]. Otherinvestigators compared the frequency of K-ras in Egypt with
western countries. It was found that K-ras was unusual in
Egyptian colorectal cancer patients (11%) vs 28–48% in wes-
tern patients with colorectal cancer. They explained this by
the fact that the pathogenesis of colorectal carcinoma in Egypt
has unique features [10]. In addition, a study was done to com-
pare K-ras frequency in the Middle East, Egypt was the lowest
18% vs 33% and 34% in Jordan and Turkish patients with
colorectal cancer, respectively [11].
Recognition of ras mutations may be helpful in screening
and early diagnosis of colorectal cancer, as well as it may be
a gate for therapeutic potentials [29]. Clinical trials revealed
that patients with none mutant K-ras had better clinical re-
sponse in terms of prolonged median progression-free survival
and overall response rates when compared to mutant K-ras
[30,31].
Frequent red meat intake as a major source of animal fat,
was associated with the increased risk of colon cancer [32–
34]. On the other hand, green leafy vegetables are thought to
be protective from CRC due to their high ﬁber content, which
in turn has many roles including diluting and binding potential
carcinogens [35]. Our patients reported a high frequency of red
meat intake, and a low frequency of green leafy vegetables.
Frequent daily intake of coffee and tea was also reported by
the patients. The caffeine and theophylline found in coffee
and tea have been shown to enhance fragile site expression in-
duced by folate restriction. i.e. act synergistically with inade-
quate folate status to augment this damage, which can
enhance carcinogenesis [36,37].
The role of folic acid in the expression of proteins involved
in proliferation, DNA repair, apoptosis, cytoskeletal organiza-
tion, and expression of proteins implicated in malignant trans-
formation has been studied [38]. It seems that the protective
effect of folic acid comes from supplements rather than higher
dietary intake, and this may be due to its lower bioavailability
when in food [39]. However, a great debate is present regarding
the association between K-ras mutation and folic acid levels.
Many researches demonstrated that the occurrence of CRC de-
pends upon the time and form of folate intake. Some reported
a lower incidence of K-ras mutated colon adenomas in individ-
uals with higher folate intake [39–42]. In contrast, Kim and
Luebeck et al. [43,44] found that folate deﬁciency has an inhib-
itory effect whereas folate supplementation has a promoting
effect on the progression of established colorectal neoplasms.
In addition, the inﬂuence of dietary folate nutrient intake on
colon cancer risk did not seem to differ with K-ras mutational
status in a study conducted by Schernhammer et al. [45].
Many evidences indicate that signiﬁcant exposure to ciga-
rette smoking is associated with an elevated risk for CRC
and could be a factor of an early onset of CRC. It may be med-
iated through the upregulation of the expression of VEGF,
resulting in the induction of cellular proliferation and angio-
genesis [46]. In our analysis, the K-ras mutation was not asso-
ciated with smoking status. This can be explained by the
method of history taking which depended on the questionnaire
of patients if positive or negative and not on the smoking index
rate.
In the present study, with the exception of the mean red
blood cell folic acid level, which was much lower in the muta-
tion positive group than the negative group this difference was
highly signiﬁcant statistically. The other studied variables did
not vary signiﬁcantly between the mutation positive and nega-
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effect of sex and folic acid on K-ras mutation. Not only did it
study the variables qualitatively, but also it measured their ef-
fects quantitatively. When the association between sex and
gene mutation was evaluated by univariate analysis, it was
non-signiﬁcant. The effect of sex was masked by signiﬁcantly
higher folate levels in males than females. Should both sexes
have similar folate levels, sex would stand out as a risk factor.
Masking of gender by the underlying folate level was unre-
vealed when multivariate analysis was conducted.
The adjusted odds ratio (OR) for RBC folic acid was 0.983
when gender was held constant (i.e. among people of the same
gender, a person is 0.983 times likely to have K-ras mutation
for each 1 ng/ml higher folate).
The adjusted OR for gender was 4.36; thus males were 4.4
times more likely to get K-ras mutation than females when
their RBCs folate levels were held constant.
The risk of development of K-ras mutation among CRC-
high-risk population could be quantiﬁed using the prediction
equation, so as to select those who require close monitoring
for the development of CRC. The degree of risk of mutation
can be anticipated, in a dose-dependent manner to folic acid
level deﬁciency. For a unit (1 ng/ml) lower folate is attended
with 1.02 risk increase, and 1.22 times more likely to get K-
ras mutation for 10 ng/ml lower folate level and 7.2 times more
risky for 100 ng/ml lower folate level.
Failure to incriminate folate level in K-ras mutation by
some researchers [45] might be attributed to masking of its ef-
fect by other factors working in opposite direction. Segrega-
tion of the effect of each variable, while holding others
constant, might underscore the signiﬁcant variables; a policy
that was followed in the current study.
COX-2 has been shown to play an important role in carci-
nogenesis in various organ systems including colon and it was
closely correlated to the prognosis of patients [47]. Both COX-
2 and K-ras produced synergistic effect in the development of
colorectal cancer [48]. However, in our study there was no
association between COX-2 genotypes and K-ras mutation.
This may be attributed to our study on the genotypes in
peripheral blood and not their expression in cancer tissues.
In conclusion, this study demonstrated that there is a po-
tential link between RBC folic acid and k-ras mutation sug-
gesting that folic acid may be a risk factor for K-ras
mutation development.
It is recommended to use the prediction model in screening
for K-ras mutation. Patients with a high calculated risk should
undergo genotyping for the K-ras genotype and should be clo-
sely monitored (e.g. radiologically, endoscopically) for early
detection of any cancerous or pre-cancerous lesions. Also,
nutritional education about decreasing consumption of red
meat and increase consumption of green leafy vegetables with
emphasis on folate-dense fruits & vegetables. Many more cases
should be studied, however, before any ﬁrm conclusions can be
drawn.
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